Suppr超能文献

照顾者报告的小儿原发性硬化性胆管炎的症状负担及对治疗目标的偏好

Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.

作者信息

Shifman Holly Payton, Hatchett Joanne, Pai Ruth-Anne, Safer Ricky, Gomel Rachel, Vyas Mary, Li Michael, Lai Jennifer C, Wadhwani Sharad I

机构信息

Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.

出版信息

J Pediatr Gastroenterol Nutr. 2024 Oct;79(4):835-840. doi: 10.1002/jpn3.12287. Epub 2024 Jun 20.

Abstract

This study analyzed qualitative and quantitative survey responses from 51 pediatric primary sclerosing cholangitis (PSC) patients and caregivers using the PSC Partners Patient Registry-Our Voices survey. The most common symptoms reported by children/caregivers include: fatigue (71%), abdominal pain (69%), anxiety (59%), appetite loss (51%), insomnia (49%), and pruritus (45%). When experiencing symptoms at their worst, over half of patients/caregivers reported limitations in physically demanding activities (67%), work/school duties (63%), social life activities (55%), and activities for fun or exercise (53%). Over half of patients/caregivers expressed willingness to participate in clinical trials, however none reported ever participating in trials for new or investigational PSC drugs. This study revealed a substantial patient/caregiver-reported symptom burden for children with PSC that impacts quality of life and limits access to clinical trials. Future efforts should focus on developing patient-centered clinical endpoints for PSC trials, increasing trial availability for pediatric PSC patients, and reducing logistical barriers to trial involvement.

摘要

本研究使用原发性硬化性胆管炎(PSC)患者伙伴登记处——我们的心声调查,分析了51名儿科原发性硬化性胆管炎患者及其护理人员的定性和定量调查回复。儿童/护理人员报告的最常见症状包括:疲劳(71%)、腹痛(69%)、焦虑(59%)、食欲减退(51%)、失眠(49%)和瘙痒(45%)。在症状最严重时,超过半数的患者/护理人员报告在体力要求较高的活动(67%)、工作/学业任务(63%)、社交活动(55%)以及娱乐或锻炼活动(53%)方面受到限制。超过半数的患者/护理人员表示愿意参与临床试验,然而无人报告曾参与过针对新型或试验性PSC药物的试验。本研究揭示,PSC患儿的患者/护理人员报告的症状负担严重,影响生活质量并限制了参与临床试验的机会。未来的工作应侧重于为PSC试验制定以患者为中心的临床终点,增加儿科PSC患者参与试验的机会,并减少参与试验的后勤障碍。

相似文献

1
Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.
J Pediatr Gastroenterol Nutr. 2024 Oct;79(4):835-840. doi: 10.1002/jpn3.12287. Epub 2024 Jun 20.
2
Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials.
Hepatol Commun. 2024 May 10;8(6). doi: 10.1097/HC9.0000000000000433. eCollection 2024 Jun 1.
4
Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis.
Clin Gastroenterol Hepatol. 2012 Jul;10(7):769-775.e2. doi: 10.1016/j.cgh.2012.01.025. Epub 2012 Feb 15.
5
Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review.
Health Qual Life Outcomes. 2018 Jul 5;16(1):133. doi: 10.1186/s12955-018-0951-6.
6
Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.
Clin Gastroenterol Hepatol. 2019 Jun;17(7):1372-1378. doi: 10.1016/j.cgh.2018.04.047. Epub 2018 Apr 26.
7
Fatigue in patients with primary sclerosing cholangitis.
Scand J Gastroenterol. 2004 Oct;39(10):961-8. doi: 10.1080/00365520410003434.
8
Symptom patterns in the daily life of PSC patients.
Liver Int. 2022 Jul;42(7):1562-1570. doi: 10.1111/liv.15271. Epub 2022 Apr 18.

本文引用的文献

1
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Hepatol Commun. 2023 May 15;7(6). doi: 10.1097/HC9.0000000000000153. eCollection 2023 Jun 1.
2
Recent Insights into Pediatric Primary Sclerosing Cholangitis.
Clin Liver Dis. 2022 Aug;26(3):489-519. doi: 10.1016/j.cld.2022.03.009. Epub 2022 Jun 25.
4
Pediatric Autoimmune Liver Diseases: Autoimmune Hepatitis and Primary Sclerosing Cholangitis.
Pediatr Clin North Am. 2021 Dec;68(6):1293-1307. doi: 10.1016/j.pcl.2021.07.006.
5
Quality of life in primary sclerosing cholangitis: a systematic review.
Health Qual Life Outcomes. 2021 Mar 20;19(1):100. doi: 10.1186/s12955-021-01739-3.
6
Grounded theory research: A design framework for novice researchers.
SAGE Open Med. 2019 Jan 2;7:2050312118822927. doi: 10.1177/2050312118822927. eCollection 2019.
7
Primary sclerosing cholangitis: A review and update.
Liver Res. 2017 Dec;1(4):221-230. doi: 10.1016/j.livres.2017.12.002.
8
Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.
Clin Gastroenterol Hepatol. 2019 Jun;17(7):1372-1378. doi: 10.1016/j.cgh.2018.04.047. Epub 2018 Apr 26.
9
Endpoints in the design of clinical trials for primary sclerosing cholangitis.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1410-1414. doi: 10.1016/j.bbadis.2017.08.015. Epub 2017 Aug 25.
10
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验